Fundraising Fox
Ansa Biotechnologies
YC W20Emeryville, US · Founded 2018 · Delaware corporation · 72 employees · 19 known investors
Find your way into Ansa Biotechnologies
Sign up to see every warm intro you have to Ansa Biotechnologies
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Ansa Biotechnologies team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Ansa provides an enzymatic DNA synthesis platform that directly synthesizes complex sequences up to 900 bp and delivers constructs up to 50 kb without assembly-based methods. It serves scientists in gene and cell therapies, antibody discovery, CDMOs, and agrigenomics.
Founders & leadership· Y Combinator alumni (W20)
Ansa Biotechnologies was founded in 2018 by Dan Lin-Arlow, Sebastian Palluk, and Daniel Hillel Lin-Arlow.
Board
Investors · 19
How we know: Carbon Silicon's portfolio page · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: Cerberus Ventures's portfolio page · Not right? Tell us
How we know: Fifty Years's portfolio page · the VCSheet dataset · Y Combinator's founder network · Not right? Tell us
How we know: Jude Gomila's portfolio page · Not right? Tell us
How we know: Metaplanet's portfolio page · the VCSheet dataset · Y Combinator's founder network · Not right? Tell us
How we know: the Y Combinator directory · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: Y Combinator's founder network · Not right? Tell us
How we know: Y Combinator's founder network · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: Y Combinator's founder network · Not right? Tell us
How we know: Y Combinator's founder network · Not right? Tell us
How we know: the VCSheet dataset · Not right? Tell us
How we know: funding news · Not right? Tell us
How we know: the VCSheet dataset · Y Combinator's founder network · Not right? Tell us
How we know: Y Combinator's founder network · Not right? Tell us
How we know: Y Combinator's founder network · Not right? Tell us
How we know: Y Combinator's founder network · Not right? Tell us
How we know: Y Combinator's founder network · Not right? Tell us
How we know: funding news · Y Combinator's founder network · Not right? Tell us
Funding
SEC filings, press & company announcements$178.6M disclosed across 5 of 6 rounds · 2020–2025
- $54.4MSeries BOct 2025 · 3 sourcesSource ↗
▶$46.4MraisedDec 2025 · 41 investors · BiotechnologyRule 506(b)
- Jason T. GammackExecutive Officer, Director
- Yanniv DoroneDirector
- Daniel Lin-ArlowExecutive Officer, Director
- Chenny ZhangDirector
- Matthew McManusDirector
- Sebastian PallukExecutive Officer
- Offering amount
- $56.9M
- Amount sold
- $46.4M
- First sale
- Jun 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$68MraisedMay 2022 · 28 investors · BiotechnologyRule 506(b)
- Daniel Lin-ArlowExecutive Officer, Director
- Sebastian PallukExecutive Officer, Director
- Lily LiDirector
- Offering amount
- $76.7M
- Amount sold
- $68M
- First sale
- Mar 2022
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$5MraisedOct 2021 · 7 investors · BiotechnologyRule 506(b)
- Sebastian PallukExecutive Officer, Director
- Daniel Lin-ArlowExecutive Officer, Director
- Offering amount
- $5M
- Amount sold
- $5M
- First sale
- Oct 2021
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$4.7MraisedJul 2020 · 24 investors · BiotechnologyRule 506(b)
- Sebastian PallukExecutive Officer, Director
- Daniel Hillel Lin-ArlowExecutive Officer, Director
- Offering amount
- $9.2M
- Amount sold
- $4.7M
- First sale
- Jun 2020
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 7
Companies working in the same space as Ansa Biotechnologies.
Non-dilutive funding · 2 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Science Foundation | Phase II | 2021 | $994.7K |
| National Science Foundation | Phase I | 2019 | $225K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Legal entities · 1
corporate structureIn the news
Frequently asked questions
- What does Ansa Biotechnologies do?
- Ansa provides an enzymatic DNA synthesis platform that directly synthesizes complex sequences up to 900 bp and delivers constructs up to 50 kb without assembly-based methods. It serves scientists in gene and cell therapies, antibody discovery, CDMOs, and agrigenomics.
- Who founded Ansa Biotechnologies?
- Ansa Biotechnologies was founded by Dan Lin-Arlow, Sebastian Palluk, Daniel Hillel Lin-Arlow in 2018.
- Who are Ansa Biotechnologies's investors?
- Ansa Biotechnologies's investors include Carbon Silicon, Cerberus Ventures, Dauntless Ventures, Fifty Years, Jude Gomila, Metaplanet, Y Combinator, Alloy Fund and 11 more.
- How much funding has Ansa Biotechnologies raised?
- Ansa Biotechnologies has disclosed $178.6M raised across 5 of its 6 known rounds.
- Where is Ansa Biotechnologies headquartered?
- Ansa Biotechnologies is headquartered in Emeryville, US.